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https://doi.org/10.1016/j.jtho.2018.02.019metastases (BMs). Approximately 10% to 20% of
patients with NSCLC also present with BM at initial diag-
nosis, and BM will develop in around 40% of them during
the course of their disease.1 The incidence of BM is
increasing on account of improved and more frequent
brain imaging and also because of more effective
systemic treatments resulting in longer overall survival
(OS). In recent years major changes in the management of
advancedNSCLC, including in patientswith BM, have taken
place. They include the introduction of immune checkpoint
inhibitors (ICIs), which have significantly modified the
therapeutic landscape. Improved OS rates have been ach-
ieved with newly available programmed death 1 (PD-1)
(nivolumab and pembrolizumab) and PD-1 ligand 1
(PD-L1) (atezolizumab and durvalumab) inhibitors.2–5
Regarding focal treatment for patients with BM, there is a
practice change away from whole brain radiotherapy
(WBRT).6 Given the high local control rates and a low
toxicity profile, stereotactic radiotherapy (SRT) delivery
has increased in the past decades.7
There is a strong rationale to combine ICIs and radio-
therapy (RT). Exposure to RT induces release of antigen
from the tumor and danger signals that induce both local
and distant anticancer immune response. However, the
tumormicroenvironment is typically immunosuppressive;
therefore, additional modulation of the immune response
using immunotherapy may be necessary to generate du-
rable immune responses in patients treated with RT.
Furthermore, ionizing radiation may increase expression
of PD-L1 on the surface of tumor cells and revert acquired
resistance to PD-1 blockade immunotherapy by limiting T-
cell exhaustion.8,9 Several preclinical studies have sug-
gested synergistic effects of RT and PD-1/PD-L1 inhibi-
tor.8,9 Nevertheless, the optimal timing of ICIs and RT is
still being debated. A preclinical study from Manchester
showed that RT delivered concurrently with an PD-1 in-
hibitor resulted in improved antitumor effects compared
with administration of the anti–PD-1 after RT.10 However
clinical evidence regarding the timing of RT and ICIs is
scarce. In a subanalysis of a phase I study (Keynote-001),better outcomes than patients who did not receive RT
(median OS 10.7 months versus 5.3 months, respectively,
hazard ratio [HR] ¼ 0.58, p ¼ 0.026). However, no details
on the delivery of cranial RT were provided.11
An important clinical concern in patients with BM is
the possible increased risk of toxicity with the adminis-
tration of an ICI before, during, or after brain irradiation.
However, there is paucity of prospective data specifically
related to the combination of ICIs and RT in patients
with NSCLC that can help guide our clinical practice. In a
nonrandomized phase II trial evaluating pembrolizumab
in untreated or progressive BM, 18 patients with PD-L1–
positive NSCLC with 46 BMs were included. Six patients
had previously received WBRT and five had received
SRT. Some patients received more than one RT course to
the brain, and for RT it was not reported if any had both
WBRT and SRT. Target lesions were defined as new
lesions or those that progressed after RT (lesions before
cranial RT were not included in the analysis). Hence, in
patients with NSCLC who had previously received
cranial RT, only three target lesions (all after WBRT,
none after SRT) were analyzed. Six of 18 patients with
NSCLC demonstrated a response to pembrolizumabJournal of Thoracic Oncology Vol. 13 No. 4: 475-477
476 Levy et al Journal of Thoracic Oncology Vol. 13 No. 4within the brain, but none of the three lesions in patients
progressing after initial WBRT responded to an ICI.
No neurological grade 3 or higher toxicities were
reported.12 Generally, in pivotal ICI trials, patients with
untreated BM have not been included, and patients with
previously treated stable BM (6%–22.2% of patients)
have not been analyzed.2–5 However, specific safety re-
sults for patients with BM were reported in a pooled
analysis of five trials with the PD-L1 inhibitor atezoli-
zumab. Five percent (79 of 1452 patients) had previ-
ously treated, stable BM. The incidence of all adverse
events (AEs) and serious AEs was similar between the
patient groups with and without BM; however, neuro-
logical AEs were numerically higher in those with BM
(all neurological AEs: 18% versus 9%; neurological
serious AEs: 6% versus 3% [no grade 4–5]; and
treatment-related grade 3 neurological AEs: 1% versus
3%).13 The most common treatment-related AEs were
headache and dizziness. No data were provided on the
toxicity profile of ICIs according to the type of previous
brain irradiation and the time interval between brain
irradiation and ICIs. Despite the paucity of prospective
data, a recent European survey on BM management in
patients with NSCLC reported that many physicians are
continuing anti–PD-1/PD-L1 therapy during SRT (129 of
462 [28%]) or WBRT (102 of 462 [22%]).14
In this issue of the Journal of Thoracic Oncology,
Hubbeling et al. provide important insights into the
combination of brain irradiation and ICIs in patients with
NSCLC, with a specific focus on the sequencing and
timing of cranial RT and the ICI. Brain RT–related AEs
were retrospectively compared between 50 ICI-treated
patients with NSCLC (31%) and 113 ICI-naive patients
with NSCLC (69%). More than one RT course was
allowed, and overall, 94 patients received SRT (70% of
ICI-treated and 52% of ICI-naive patients), 28 patients
received partial brain RT (16% of ICI-treated and 18% of
ICI-naive patients, with most [66%] receiving it post-
operatively), and 101 received WBRT (58% of ICI-
treated and 64% of ICI-naive patients). ICI-treated pa-
tients received more RT courses (>1 course: 43% of ICI-
negative versus 64% of ICI-treated patients [p ¼ 0.02]),
and more SRT sessions (a median of two SRT sessions in
ICI-treated patients versus one in ICI-naive patients [p ¼
0.003]) than did ICI-naive patients. In terms of timing,
RT was most frequently administered before (n ¼ 31) or
concurrently with (n ¼ 20) the ICI. It should be noted
that the definition of concurrent administration was
delivery of RT 4 weeks or less before or after ICI. At a
median follow-up duration from first RT treatment of 16
months (range 1–140 months), no significant difference
was observed in the rate of all-grade RT-related AEs
(including treatment-related imaging change) between
ICI-treated and ICI-naive patients. For any particularcranial RT type, the incidence of grade 3 or higher AEs
was 8% to 13% across treatment groups. The most
frequently observed grade 3 or higher AEs in ICI-positive
patients were headache (n ¼ 2), anorexia (n ¼ 2), and
cognitive disturbance (n ¼ 2). Importantly there were
also no significant differences in rates of AEs based on
the sequencing of RT and ICI.15
The authors should be congratulated for providing
detailed data on a large cohort to date of patients with
NSCLC treated with cranial RT and an ICI. Two other
retrospective studies focusing on the outcome of pa-
tients with NSCLC with BM who received both RT and an
anti–PD-1/PD-L1 inhibitor did not report severe neuro-
logical toxicity.16,17 However, it should be emphasized
that evaluating toxicity retrospectively is challenging, as
it can be difficult to distinguish, for example, radiation
necrosis (RN) or pseudoprogression from brain pro-
gression. A recently published retrospective series re-
ported higher RN risks when combining ICI and SRT in
patients with BM. Among 480 patients with BM (289
[61%] of 480 NSCLC) who had been treated with SRT,
115 (24%) received an anti-PD1 (nivolumab or pem-
brolizumab) or an anti–cytotoxic T-lymphocyte associ-
ated protein 4 (ipilimumab). Patients treated with ICI
had a significantly higher rate of symptomatic RN after
adjustment for tumor type (HR ¼ 2.6, p ¼ 0.004). Risk of
neurotoxicity was highest for patients with melanoma
treated with ipilimumab (HR ¼ 4.7, p ¼ 0.01).18 Another
point for discussion is whether assessing toxicity by
using the Common Terminology Criteria for Adverse
Events scale is the most clinically relevant way of
assessing the safety of the combination of an ICI and
cranial irradiation. Specific neurocognitive tests and
quality of life data should ideally be reported, but this is
rarely done outside the context of prospective trials. As
highlighted by Hubbeling et al., small heterogeneous
selected data sets of patients are not sufficient to draw
firm conclusions on the safety of the combination of
cranial irradiation with an ICI. In particular, it should be
noted that in their study, only 20 patients received cra-
nial irradiation concurrently with an ICI.15
Many questions regarding the combination of an ICI
and brain irradiation remain unanswered and should
ideally be tested in a prospective fashion. The impact of
steroids, which are frequently prescribed for BM symp-
tom management, in this group of patients is unknown.
There are no prospective data on the influence of tumor
histologic type or type of ICI used (PD-1/PD-L1 or
cytotoxic T-lymphocyte associated protein 4 inhibition)
on the risk of ICI-RT–induced neurotoxicity. Optimal
timing and dose fractionation is currently under inves-
tigation in prospective trials enrolling patients with
NSCLC with BM. Concurrent ICI and brain RT adminis-
tration (starting during the first ICI cycle) is being
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first (NCT02858869) is a phase I trial testing three
different schemes of brain SRT (30 Gy in five fractions,
27 Gy in three fractions, or 21 Gy in a single fraction)
with pembrolizumab in patients with NSCLC or mela-
noma. The second is a phase I/II (NCT02696993) non-
randomized trial evaluating nivolumab with or without
ipilimumab with either SRT (at a dosage prescribed by
the treating physician) or WBRT in patients with NSCLC.
The third is a phase II trial from Canada (NCT02978404)
enrolling patients with renal cell carcinoma or NSCLC
who will receive radiosurgery (15–20 Gy in a single
fraction) during the first cycle of nivolumab. Another
important question is how best to assess response after
SRT and an ICI and differentiate between progression,
possible RN, or pseudoprogression. This question is be-
ing addressed in a phase II study evaluating magnetic
resonance imaging with ferumoxytol as a contrast agent
after combination treatment (NCT03325166). Finally,
given that brain response rates were comparable to
extracranial response rates in the study by Goldberg
et al., whether ICI without RT is a valid option for pa-
tients with NSCLC with asymptomatic BM should be
evaluated. Ultimately, ancillary studies are needed to
validate companion predictive biomarkers at the cellular
(tumor microenvironment composition), genomic
(mutational/neoantigen load), and peripheral (blood and
stools) levels. This will allow oncologists to better select
patients who could benefit from promising but expen-
sive therapeutic combinations.8,9References
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